Core Viewpoint - Recently, the company announced that it received a payment of $40 million from AbbVie as part of a milestone payment under the overseas licensing option agreement for the investigational new candidate drug SIM0500 [1] Group 1: Financial Details - The agreement includes an upfront payment and potential milestone payments totaling up to $1.055 billion [1] - The company will also receive tiered royalties based on net sales [1] Group 2: Development Progress - The receipt of this payment signifies positive progress in the clinical development collaboration between the company and AbbVie for SIM0500 [1]